<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Nyanhete TE</submitter><funding>National Institute of Allergy and Infectious Diseases</funding><funding>NIAID NIH HHS</funding><funding>Center for AIDS Research, Duke University</funding><funding>National Institutes of Health</funding><pagination>670561</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8733328</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>12</volume><pubmed_abstract>Broadly neutralizing antibodies (bNAbs), known to mediate immune control of HIV-1 infection, only develop in a small subset of HIV-1 infected individuals. Despite being traditionally associated with patients with high viral loads, bNAbs have also been observed in therapy naïve HIV-1+ patients naturally controlling virus replication [Virus Controllers (VCs)]. Thus, dissecting the bNAb response in VCs will provide key information about what constitutes an effective humoral response to natural HIV-1 infection. In this study, we identified a polyclonal bNAb response to natural HIV-1 infection targeting CD4 binding site (CD4bs), V3-glycan, gp120-gp41 interface and membrane-proximal external region (MPER) epitopes on the HIV-1 envelope (Env). The polyclonal antiviral antibody (Ab) response also included antibody-dependent cellular phagocytosis of clade AE, B and C viruses, consistent with both the Fv and Fc domain contributing to function. Sequence analysis of &lt;i>envs&lt;/i> from one of the VCs revealed features consistent with potential immune pressure and virus escape from V3-glycan targeting bNAbs. Epitope mapping of the polyclonal bNAb response in VCs with bNAb activity highlighted the presence of gp120-gp41 interface and CD4bs antibody classes with similar binding profiles to known potent bNAbs. Thus, these findings reveal the induction of a broad and polyfunctional humoral response in VCs in response to natural HIV-1 infection.</pubmed_abstract><journal>Frontiers in immunology</journal><pubmed_title>Polyclonal Broadly Neutralizing Antibody Activity Characterized by CD4 Binding Site and V3-Glycan Antibodies in a Subset of HIV-1 Virus Controllers.</pubmed_title><pmcid>PMC8733328</pmcid><funding_grant_id>R01 AI145687</funding_grant_id><funding_grant_id>R01 AI131722</funding_grant_id><funding_grant_id>UM1 AI100645</funding_grant_id><funding_grant_id>P01 AI120756</funding_grant_id><funding_grant_id>R56 AI052779</funding_grant_id><pubmed_authors>Janowska K</pubmed_authors><pubmed_authors>Spreng RL</pubmed_authors><pubmed_authors>Mansouri K</pubmed_authors><pubmed_authors>Goodman D</pubmed_authors><pubmed_authors>Zhang L</pubmed_authors><pubmed_authors>Dennison SM</pubmed_authors><pubmed_authors>Bradley T</pubmed_authors><pubmed_authors>Nyanhete TE</pubmed_authors><pubmed_authors>Edwards RJ</pubmed_authors><pubmed_authors>Acharya P</pubmed_authors><pubmed_authors>Eaton A</pubmed_authors><pubmed_authors>LaBranche CC</pubmed_authors><pubmed_authors>Hora B</pubmed_authors><pubmed_authors>Hope TJ</pubmed_authors><pubmed_authors>Georgiev IS</pubmed_authors><pubmed_authors>Montefiori DC</pubmed_authors><pubmed_authors>Mudrak SV</pubmed_authors><pubmed_authors>Tomaras GD</pubmed_authors><pubmed_authors>Saunders KO</pubmed_authors></additional><is_claimable>false</is_claimable><name>Polyclonal Broadly Neutralizing Antibody Activity Characterized by CD4 Binding Site and V3-Glycan Antibodies in a Subset of HIV-1 Virus Controllers.</name><description>Broadly neutralizing antibodies (bNAbs), known to mediate immune control of HIV-1 infection, only develop in a small subset of HIV-1 infected individuals. Despite being traditionally associated with patients with high viral loads, bNAbs have also been observed in therapy naïve HIV-1+ patients naturally controlling virus replication [Virus Controllers (VCs)]. Thus, dissecting the bNAb response in VCs will provide key information about what constitutes an effective humoral response to natural HIV-1 infection. In this study, we identified a polyclonal bNAb response to natural HIV-1 infection targeting CD4 binding site (CD4bs), V3-glycan, gp120-gp41 interface and membrane-proximal external region (MPER) epitopes on the HIV-1 envelope (Env). The polyclonal antiviral antibody (Ab) response also included antibody-dependent cellular phagocytosis of clade AE, B and C viruses, consistent with both the Fv and Fc domain contributing to function. Sequence analysis of &lt;i>envs&lt;/i> from one of the VCs revealed features consistent with potential immune pressure and virus escape from V3-glycan targeting bNAbs. Epitope mapping of the polyclonal bNAb response in VCs with bNAb activity highlighted the presence of gp120-gp41 interface and CD4bs antibody classes with similar binding profiles to known potent bNAbs. Thus, these findings reveal the induction of a broad and polyfunctional humoral response in VCs in response to natural HIV-1 infection.</description><dates><release>2021-01-01T00:00:00Z</release><publication>2021</publication><modification>2024-11-15T03:33:48.069Z</modification><creation>2022-02-11T15:06:08.942Z</creation></dates><accession>S-EPMC8733328</accession><cross_references><pubmed>35003053</pubmed><doi>10.3389/fimmu.2021.670561</doi></cross_references></HashMap>